News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,082 Results
Type
Article (57558)
Company Profile (436)
Press Release (668072)
Multimedia
Podcasts (218)
Webinars (31)
Section
Business (190199)
Career Advice (3284)
Deals (32742)
Drug Delivery (151)
Drug Development (83840)
Employer Resources (185)
FDA (16619)
Job Trends (14555)
News (331124)
Policy (32336)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (2884)
Academic (2)
Accelerated approval (56)
ADA (49)
Adcomms (42)
Allergies (203)
Alliances (49675)
ALS (235)
Alzheimer's disease (1925)
Antibody-drug conjugate (ADC) (547)
Approvals (16994)
Artificial intelligence (805)
ASCO (343)
Autoimmune disease (359)
Automation (63)
Bankruptcy (312)
Best Places to Work (11577)
BIOSECURE Act (20)
Biosimilars (234)
Biotechnology (310)
Bladder cancer (210)
Brain cancer (83)
Breast cancer (824)
Cancer (6508)
Cardiovascular disease (541)
Career advice (2810)
Career pathing (51)
CAR-T (387)
CDC (64)
Celiac Disease (3)
Cell therapy (1069)
Cervical cancer (55)
Clinical research (72946)
Collaboration (2338)
Commercialization (1)
Company closure (8)
Compensation (1438)
Complete response letters (104)
COVID-19 (2823)
CRISPR (125)
C-suite (1229)
Cystic fibrosis (168)
Data (8725)
Decentralized trials (3)
Denatured (80)
Depression (190)
Dermatology (97)
Diabetes (694)
Diagnostics (6767)
Digital health (65)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (406)
Drug pricing (216)
Drug shortages (37)
Duchenne muscular dystrophy (319)
Earnings (81282)
Editorial (79)
Employer branding (23)
Employer resources (165)
Events (122806)
Executive appointments (1117)
FDA (20610)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (36)
Funding (1901)
Gene editing (269)
Generative AI (79)
Gene therapy (855)
GLP-1 (1206)
Government (5024)
Grass and pollen (8)
Guidances (412)
Healthcare (19607)
Hematology (191)
HIV (97)
Huntington's disease (65)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (114)
Immunology and inflammation (344)
Immuno-oncology (111)
Indications (211)
Infectious disease (3198)
Inflammatory bowel disease (240)
Inflation Reduction Act (17)
Influenza (142)
Intellectual property (319)
Interviews (646)
IPO (15626)
IRA (56)
Job creations (3325)
Job search strategy (2257)
JPM (71)
Kidney cancer (22)
Labor market (107)
Layoffs (602)
Leadership (53)
Legal (7399)
Liver cancer (104)
Longevity (33)
Lung cancer (851)
Lymphoma (481)
Machine learning (62)
Management (64)
Manufacturing (1171)
Marketing (1)
MASH (223)
Medical affairs (1)
Medical device (13390)
Medtech (13534)
Mergers & acquisitions (18458)
Metabolic disorders (1771)
mRNA (261)
Multiple sclerosis (199)
NASH (22)
Neurodegenerative disease (496)
Neuropsychiatric disorders (123)
Neuroscience (3645)
Neurotech (1)
NextGen: Class of 2026 (6787)
Non-profit (4782)
Now hiring (62)
Obesity (831)
Opinion (369)
Ovarian cancer (244)
Pain (281)
Pancreatic cancer (351)
Parkinson's disease (415)
Partnered (38)
Patents (637)
Patient recruitment (762)
Peanut (68)
People (56097)
Pharmaceutical (77)
Pharmacy benefit managers (36)
Phase 1 (22803)
Phase 2 (32041)
Phase 3 (23996)
Pipeline (9745)
Policy (374)
Postmarket research (2743)
Preclinical (9845)
Press Release (68)
Prostate cancer (350)
Psychedelics (69)
Radiopharmaceuticals (368)
Rare diseases (1268)
Real estate (5556)
Recruiting (78)
Regulatory (25847)
Reports (52)
Research institute (2607)
Resumes & cover letters (521)
Rett syndrome (43)
RNA editing (30)
RSV (90)
Schizophrenia (194)
Series A (323)
Series B (239)
Service/supplier (10)
Sickle cell disease (128)
Special edition (32)
Spinal muscular atrophy (179)
Sponsored (54)
Startups (3489)
State (2)
Stomach cancer (20)
Supply chain (136)
Tariffs (89)
The Weekly (135)
Vaccines (1190)
Venture capital (130)
Weight loss (559)
Women's health (130)
Worklife (24)
Date
Last 7 days (519)
Last 30 days (2550)
Last 365 days (31488)
2026 (16010)
2025 (31362)
2024 (36022)
2023 (40384)
2022 (51155)
2021 (55504)
2020 (53750)
2019 (46851)
2018 (35501)
2017 (32856)
2016 (32746)
2015 (37748)
2014 (31014)
2013 (26388)
2012 (27501)
2011 (27760)
2010 (26109)
Location
Africa (973)
Alabama (95)
Alaska (7)
Arizona (314)
Arkansas (16)
Asia (42351)
Australia (7376)
California (13875)
Canada (3920)
China (1552)
Colorado (582)
Connecticut (615)
Delaware (428)
Europe (99059)
Florida (2080)
Georgia (447)
Hawaii (3)
Idaho (62)
Illinois (1141)
India (102)
Indiana (620)
Iowa (24)
Japan (593)
Kansas (132)
Kentucky (52)
Louisiana (61)
Maine (71)
Maryland (1646)
Massachusetts (10253)
Michigan (394)
Minnesota (743)
Mississippi (6)
Missouri (149)
Montana (33)
Nebraska (26)
Nevada (143)
New Hampshire (86)
New Jersey (3678)
New Mexico (34)
New York (3654)
North Carolina (1842)
North Dakota (10)
Northern California (6923)
Ohio (419)
Oklahoma (25)
Oregon (41)
Pennsylvania (2749)
Puerto Rico (29)
Rhode Island (51)
South America (1291)
South Carolina (81)
Southern California (5526)
Tennessee (218)
Texas (2219)
United States (49391)
Utah (394)
Vermont (2)
Virginia (349)
Washington D.C. (78)
Washington State (1146)
West Virginia (4)
Wisconsin (136)
Wyoming (2)
726,082 Results for "the leukemia and lymphoma society".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
BeOne wins mantle cell lymphoma approval, opening new therapy class
Beqalzi is the first BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma.
May 14, 2026
·
2 min read
·
Tristan Manalac
Lymphoma
ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug
In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.
June 4, 2026
·
2 min read
·
Tristan Manalac
CAR-T
Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study
All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer.
June 3, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
March 2, 2026
·
9 min read
Press Releases
AstraZeneca Canada & the Leukemia & Lymphoma Society of Canada announce winners of the 2025 Operating Grants in Blood Cancer
November 6, 2025
·
4 min read
Press Releases
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
January 28, 2026
·
3 min read
Press Releases
U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma
January 21, 2026
·
4 min read
Press Releases
The Leukemia & Lymphoma Society Welcomes Three New Members to its Board of Directors
July 2, 2025
·
5 min read
BioCapital
Eilean Therapeutics Joins The Leukemia & Lymphoma Society’s Groundbreaking Beat AML® Master Clinical Trial
Eilean Therapeutics AU Pty Ltd has joined The Leukemia & Lymphoma Society in the groundbreaking collaborative Beat AML® Master Clinical Trial.
June 11, 2024
·
4 min read
Press Releases
Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
January 28, 2026
·
9 min read
1 of 72,609
Next
